Technical Analysis for BRTX - BioRestorative Therapies, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Gapped Up | Strength | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.72% | |
Inside Day | Range Contraction | 0.72% | |
Below Lower BB | Weakness | 0.72% | |
Gapped Down | Weakness | 0.72% | |
Lower Bollinger Band Touch | Weakness | 0.72% |
Alert | Time |
---|---|
Possible NR7 | about 18 hours ago |
60 Minute Opening Range Breakdown | about 21 hours ago |
Rose Above Previous Day's High | about 22 hours ago |
Rose Above Lower Bollinger Band | about 22 hours ago |
Up 3% | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/11/2024
BioRestorative Therapies, Inc. Description
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate, which is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue (BAT). In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Stem Cell Cell Therapy Cell Biology Obesity Therapeutic Products Regenerative Medicine Metabolic Disorders Adult Stem Cell Mesenchymal Stem Cell Stem Cell Therapy Non Surgical Treatment
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.6699 |
52 Week Low | 1.03 |
Average Volume | 27,887 |
200-Day Moving Average | 1.52 |
50-Day Moving Average | 1.63 |
20-Day Moving Average | 1.54 |
10-Day Moving Average | 1.51 |
Average True Range | 0.14 |
RSI (14) | 37.50 |
ADX | 22.84 |
+DI | 15.45 |
-DI | 21.19 |
Chandelier Exit (Long, 3 ATRs) | 1.37 |
Chandelier Exit (Short, 3 ATRs) | 1.64 |
Upper Bollinger Bands | 1.70 |
Lower Bollinger Band | 1.37 |
Percent B (%b) | 0.08 |
BandWidth | 21.47 |
MACD Line | -0.06 |
MACD Signal Line | -0.04 |
MACD Histogram | -0.0202 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.49 | ||||
Resistance 3 (R3) | 1.49 | 1.47 | 1.48 | ||
Resistance 2 (R2) | 1.47 | 1.44 | 1.47 | 1.47 | |
Resistance 1 (R1) | 1.43 | 1.43 | 1.42 | 1.43 | 1.46 |
Pivot Point | 1.41 | 1.41 | 1.40 | 1.41 | 1.41 |
Support 1 (S1) | 1.37 | 1.38 | 1.36 | 1.37 | 1.34 |
Support 2 (S2) | 1.35 | 1.37 | 1.35 | 1.33 | |
Support 3 (S3) | 1.31 | 1.35 | 1.33 | ||
Support 4 (S4) | 1.31 |